Key Takeaways AbbVie agreed to license a weight-loss drug in development from Danish biotech firm Gubra.AbbVie said it will pay up to about $2.2 billion for the drug GUBamy, which is currently in a Phase 1 clinical trial.

A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with drugs from Novo Nordisk, Eli Lilly and Zealand.

The obesity medicine field has gained a new entrant, with AbbVie licensing an experimental drug from a Danish company.

AbbVie has signed a licensing deal with Gubra A/S to develop an obesity drug, marking the North Chicago company's first foray into the obesity market.

The licensing deal could set the US drugmaker to vie with Eli Lilly & Co. and Novo Nordisk A/S, the current leaders in a market that's expected to reach $130 billion in annual sales by 2030

AbbVie ABBV announced that it has entered into a licensing agreement with Denmark-based biotech Gubra for the latter’s experimental obesity drug, GUB014295. This marks the American drugmaker’s foray into the lucrative obesity market.

AbbVie is entering the obesity treatment market with a $2.3bn licensing agreement to acquire global rights to GUB014295, a long-acting amylin analogue developed by Danish biotech Gubra. Announced on 3 March,